Dragon Biotechnologies provides engineered animal cell lines for applications such as animal‑free drug discovery and cultivated meat production. Their catalog offers a broad range of precision‑engineered cell types, and they also deliver custom cell‑line solutions to help customers accelerate research, development, and commercial scaling.
Funding
Funding not disclosed
Founders
Product
Problem
Researchers in drug discovery and cultivated meat development often spend extensive time sourcing and validating animal cell lines that meet specific performance and reproducibility criteria. Inconsistent cell quality and limited availability of engineered lines hinder rapid experimentation and scale‑up, increasing project timelines and costs.
Solution
Dragon Biotechnologies supplies precision‑engineered animal cell lines that are well‑characterized and optimized for robust performance across discovery, development, and manufacturing stages. Their catalog offers a broad selection of immortalized lines—including porcine iPSCs, bovine fibroblasts, and adipocyte‑derived stem cells—each engineered for stability, scalability, and relevance to animal‑free drug testing and cultivated meat production. For projects with unique requirements, the company provides custom cell‑line engineering services such as immortalization, suspension adaptation, and iPSC reprogramming. Complementary media formulations, like Lacey’s PluriPlus, support consistent maintenance of pluripotency during large‑scale expansion. All products are delivered with detailed data packs and technical support to accelerate experimental design and reduce translational barriers.
Target Audience
Primary customers are R&D teams in pharmaceutical companies developing animal‑free drug screening assays and cultivated meat producers requiring scalable, reliable cell platforms for product development.
Features
- Wide catalog of species‑specific immortalized cell lines (porcine, bovine, etc.) with documented growth and differentiation characteristics
- Custom engineering services including cell‑line immortalization, suspension adaptation, and iPSC reprogramming
- Chemically defined, serum‑free media (e.g., Lacey’s PluriPlus) optimized for maintaining pluripotency in large‑scale cultures
- Comprehensive data packs providing genomic, phenotypic, and performance metrics for each cell line
- Matched primary cell line options and differentiation kits to streamline downstream assay development
- Bioprocess development support to facilitate scale‑up from bench to commercial production